


Listing of Claims:

1. A compound having the Formula I:



or a pharmaceutically acceptable salt thereof, wherein

5 X and Y are each independently CR^d or N;

R¹ is , monocyclic C₃₋₆ cycloalkyl, or 4- to 7-membered monocyclic

heterocyclyl, wherein said cycloalkyl and heterocyclyl are optionally substituted with one or more R^a;

10 R² is C₁₋₄haloalkyl, phenyl, or monocyclic C₃₋₆ cycloalkyl optionally substituted with one or more R^b;

R³ is hydrogen, C₁₋₄alkyl, or C₁₋₄haloalkyl;

R⁴ is hydrogen or C₁₋₄alkyl;

R⁵ is halo;

15 R⁶ is C₁₋₄alkyl or C₁₋₄haloalkyl, wherein said C₁₋₄alkyl or C₁₋₄haloalkyl are each substituted with OR^c;


t is 0, 1, or 2;


R^a and R^b are each independently selected from is selected from halo, C₁₋₄alkyl, C₁₋₄haloalkyl, C₁₋₄alkoxy, and C₁₋₄haloalkoxy,

20 R^c is C₁₋₄alkyl optionally substituted with C₃₋₆ cycloalkyl or C₁₋₄alkoxy, or C₃₋₆ cycloalkyl; and

R^d is hydrogen or C₁₋₄alkyl;


provided the compound is not a compound having the formula:



or ; or a pharmaceutically acceptable salt thereof.


25

2. The compound of claim 1, wherein the compound is of the Formula I-a:




or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in claim 1.

3. The compound of claim 1 or 2, wherein the compound is of the Formula I-b:




or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in claim 1.

4. The compound of claim 1 or 2, wherein the compound is of the Formula II:




or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in claim 1.

5. The compound of claim 1, 2 or 4, wherein the compound is of the Formula III:




or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in claim 1.

6. The compound of claim 1, wherein the compound is of the Formula I-c:



or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in claim 1.


7. A compound having the Formula I-d:



or a pharmaceutically acceptable salt thereof, wherein


- 5 R^1 is R^3 R^4 , monocyclic C_{3-6} cycloalkyl, or 4- to 7-membered monocyclic heterocyclyl, wherein said cycloalkyl and heterocyclyl are optionally substituted with one or more R^a ;
- R^2 is C_{1-4} haloalkyl, phenyl, or monocyclic C_{3-6} cycloalkyl optionally substituted with one or more R^b ;
- R^3 is hydrogen, C_{1-4} alkyl, or C_{1-4} haloalkyl;
- R^4 is hydrogen or C_{1-4} alkyl;
- 10 R^5 is halo;
- R^6 is C_{1-4} alkyl or C_{1-4} haloalkyl, wherein said C_{1-4} alkyl or C_{1-4} haloalkyl are each substituted with OR^c ;
- t is 0, 1, or 2;
- R^a and R^b are each independently selected from is selected from halo, C_{1-4} alkyl, C_{1-4} haloalkyl, C_{1-4} alkoxy, and C_{1-4} haloalkoxy;
- 15 R^c is C_{1-4} alkyl optionally substituted with C_{3-6} cycloalkyl or C_{1-4} alkoxy, or C_{3-6} cycloalkyl; and
- R^d is hydrogen or C_{1-4} alkyl.

- 20 8. The compound of any one of claims 1-5 and 7, wherein the compound is of the Formula V:




or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in claim 1.

- 25 9. The compound of any one of claims 1, 6, and 7, wherein the compound is of the Formula VII:




or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in claim 1.

10. The compound of any one of claims 1-5, wherein the compound is of the Formula
5 VIII:



or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in claim 1.

11. The compound of any one of claims 1-5, wherein the compound is of the Formula
10 VIII:



or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in claim 1.

12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt

thereof, wherein R¹ is .

15


13. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt
thereof, wherein R¹ is cyclobutyl optionally substituted with one or more Rᵃ.


14. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt
20 thereof, wherein R² is C₁-₄haloalkyl.


15. The compound of any one of claims 1-12 and 14, or a pharmaceutically acceptable
salt thereof, wherein R² is CF₃.


16. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, wherein R^2 is phenyl.
- 5 17. The compound of any one of claims 1-12 and 14-16, or a pharmaceutically acceptable salt thereof, wherein R^3 is C_{1-4} alkyl and R^4 is hydrogen or C_{1-4} alkyl.
18. The compound of any one of claims 1-12 and 14-17, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 are each C_{1-4} alkyl.
- 10 19. The compound of any one of claims 1-12 and 14-18, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 are each methyl.
20. The compound of any one of claims 1-12 and 14-17, or a pharmaceutically acceptable salt thereof, wherein R^3 is methyl and R^4 is hydrogen.
- 15 21. The compound of any one of claims 1-12 and 14-16, or a pharmaceutically acceptable salt thereof, wherein R^3 and R^4 are each hydrogen.
- 20 22. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein R^6 is $-CF_2-OR^c$.
23. The compound of any one of claims 1-22, or a pharmaceutically acceptable salt thereof, wherein R^c is C_{1-4} alkyl optionally substituted with cyclopropyl.
- 25 24. The compound of any one of claims 1-22, or a pharmaceutically acceptable salt thereof, wherein R^c is cyclopropyl.
25. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein R^6 is $-C(F_2)OCH_2CH(CH_3)_2$, $-C(F_2)OCH_3$, $-C(F_2)OCH_2CH_3$, $-C(F_2)OCH(CH_3)_2$, or $-C(F_2)OCH_2C_3H_5$.
- 30 26. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein R^6 is $-CH_2-OR^c$.


27. The compound of any one of claims 1-21 and 26, or a pharmaceutically acceptable salt thereof, wherein R^c is C_{1-4} alkyl.
28. The compound of any one of claims 1-21, 26, and 27, or a pharmaceutically acceptable salt thereof, wherein R^6 is $-\text{CH}_2\text{OCH}_3$, $-\text{CH}_2\text{OCH}_2\text{CH}_3$, or $-\text{CH}_2\text{OCH}_2\text{CH}(\text{CH}_3)_2$.
29. The compound of any one of claims 1-11, 13, and 22-28, or a pharmaceutically acceptable salt thereof, wherein R^a is C_{1-4} haloalkyl.
30. The compound of any one of claims 1-11, 13, and 22-29, or a pharmaceutically acceptable salt thereof, wherein R^a is CF_3 .
31. The compound of any one of claims 1-11, 13, and 22-28, or a pharmaceutically acceptable salt thereof, wherein R^a is fluoro.
32. The compound of any one of claims 1, 7, and 12-31, or a pharmaceutically acceptable salt thereof, wherein t is 1.
33. The compound of any one of claims 1, 7 and 12-31, or a pharmaceutically acceptable salt thereof, wherein t is 0.
34. The compound of any one of claims 1-7 and 12-33, or a pharmaceutically acceptable salt thereof, wherein R^d is methyl.
35. The compound of any one of claims 1-7 and 12-33, or a pharmaceutically acceptable salt thereof, wherein R^d is hydrogen.
36. The compound of claim 1, wherein the compound is selected from the group consisting of:




















5 pharmaceutically acceptable salt thereof.

37. The compound of claim 36, wherein the compound is selected from the group consisting of:





38. A crystalline compound of formula:



5

wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 6.9 ± 0.2 , 16.5 ± 0.2 , and 20.8 ± 0.2 .

39. The crystalline compound of claim 38, wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 6.9 ± 0.2 , 13.9 ± 0.2 , 16.5 ± 0.2 , 19.5 ± 0.2 , and 20.8 ± 0.2 .

40. The crystalline compound of claim 38 or 39, wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 6.9 ± 0.2 , 11.2 ± 0.2 , 13.9 ± 0.2 , 16.5 ± 0.2 , 17.4 ± 0.2 , 18.1 ± 0.2 , 19.1 ± 0.2 , 19.5 ± 0.2 , and 20.8 ± 0.2 .


41. The crystalline compound of any one of claims 38-40, wherein the crystalline compound exhibits an X-ray powder diffraction pattern substantially the same as depicted in FIG. 2A.

42. The crystalline compound of any one of claims 38-41, wherein the crystalline compound has a melting point onset as determined by differential scanning calorimetry at about 140°C .

43. The crystalline compound of any one of claims 38-42, wherein the crystalline compound has a differential scanning calorimetry curve substantially the same as shown in FIG. 2B.

5

44. A crystalline compound of formula:



wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 16.7 ± 0.2 , 19.0 ± 0.2 , and 20.4 ± 0.2 .

10

45. The crystalline compound of claim 43, wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 7.2 ± 0.2 , 14.4 ± 0.2 , 16.7 ± 0.2 , 19.0 ± 0.2 , 20.4 ± 0.2 , and 25.7 ± 0.2 .

15 46. The crystalline compound of claim 44 or 45, wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 7.2 ± 0.2 , 14.4 ± 0.2 , 16.7 ± 0.2 , 17.9 ± 0.2 , 19.0 ± 0.2 , 20.4 ± 0.2 , 20.8 ± 0.2 , 23.2 ± 0.2 , 25.7 ± 0.2 , and 28.0 ± 0.2 .


20 47. The crystalline compound of any one of claims 44-46, wherein the crystalline compound exhibits an X-ray powder diffraction pattern substantially the same as depicted in FIG. 3A.

25 48. The crystalline compound of any one of claims 44-47, wherein the crystalline compound has a melting point onset as determined by differential scanning calorimetry at about 68°C .

49. The crystalline compound of any one of claims 44-48, wherein the crystalline compound has a differential scanning calorimetry curve substantially the same as shown in FIG. 3B.

30

50. A crystalline compound of formula:



wherein the crystalline compound exhibits an X-ray powder diffraction pattern
5 comprising peaks at the following diffraction angles (2θ): 7.3 ± 0.2 , 14.5 ± 0.2 , and 21.9 ± 0.2 .

51. The crystalline compound of claim 50, wherein the crystalline compound exhibits an
X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
 7.3 ± 0.2 , 14.5 ± 0.2 , 17.9 ± 0.2 , 19.0 ± 0.2 , and 21.9 ± 0.2 .

10

52. The crystalline compound of claim 50 or 51, wherein the crystalline compound
exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction
angles (2θ): 7.3 ± 0.2 , 13.7 ± 0.2 , 14.5 ± 0.2 , 17.9 ± 0.2 , 19.0 ± 0.2 , 20.3 ± 0.2 , 21.9 ± 0.2 , 24.7 ± 0.2 ,
and 25.4 ± 0.2 .


15

53. The crystalline compound of any one of claims 50-52, wherein the crystalline
compound exhibits an X-ray powder diffraction pattern substantially the same as depicted in
FIG. 4A.

20 54. The crystalline compound of any one of claims 50-53, wherein the crystalline
compound has a melting point onset as determined by differential scanning calorimetry at
about 136°C .

55. The crystalline compound of any one of claims 50-54, wherein the crystalline
25 compound has a differential scanning calorimetry curve substantially the same as shown in
FIG. 4B.

56. A crystalline compound of formula:



wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 12.6±0.2, 15.8±0.2, and 18.6±0.2.

5 57. The crystalline compound of claim 56, wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 10.7±0.2, 12.3±0.2, 12.6±0.2, 15.8±0.2, 18.6±0.2, and 22.6±0.2.

58. The crystalline compound of claim 56 or 57, wherein the crystalline compound
10 exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 10.7±0.2, 12.3±0.2, 12.6±0.2, 14.9±0.2, 15.8±0.2, 16.6±0.2, 16.8±0.2, 18.6±0.2, 21.0±0.2 and 22.6±0.2.


59. The crystalline compound of any one of claims 56-58, wherein the crystalline
15 compound exhibits an X-ray powder diffraction pattern substantially the same as depicted in FIG. 5A.

60. The crystalline compound of any one of claims 56-59, wherein the crystalline
20 compound has a melting point onset as determined by differential scanning calorimetry at about 107 °C.

61. The crystalline compound of any one of claims 56-60, wherein the crystalline
compound has a differential scanning calorimetry curve substantially the same as shown in
FIG. 5B.

25

62. A crystalline compound of formula:



wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 5.8 ± 0.2 , 19.7 ± 0.2 , and 21.0 ± 0.2 .

63. The crystalline compound of claim 62, wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 5.8 ± 0.2 , 14.5 ± 0.2 , 15.3 ± 0.2 , 19.7 ± 0.2 , 21.0 ± 0.2 , and 24.2 ± 0.2 .


64. The crystalline compound of claim 62 or 63, wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 5.8 ± 0.2 , 11.6 ± 0.2 , 12.0 ± 0.2 , 14.5 ± 0.2 , 15.3 ± 0.2 , 19.1 ± 0.2 , 19.7 ± 0.2 , 21.0 ± 0.2 , 22.4 ± 0.2 , and 24.2 ± 0.2 .

65. The crystalline compound of any one of claims 62-64, wherein the crystalline compound exhibits an X-ray powder diffraction pattern substantially the same as depicted in FIG. 6A.

66. The crystalline compound of any one of claims 62-65, wherein the crystalline compound has a melting point onset as determined by differential scanning calorimetry at about $94\text{ }^{\circ}\text{C}$.

67. The crystalline compound of any one of claims 62-66, wherein the crystalline compound has a differential scanning calorimetry curve substantially the same as shown in FIG. 6B.

68. A crystalline compound of formula:



wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 7.3 ± 0.2 , 16.6 ± 0.2 , and 18.4 ± 0.2 .

69. The crystalline compound of claim 68, wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2 θ): 7.3 $\pm$ 0.2, 13.8 $\pm$ 0.2, 16.6 $\pm$ 0.2, 18.4 $\pm$ 0.2, 20.3 $\pm$ 0.2, and 24.3 $\pm$ 0.2.


5 70. The crystalline compound of claim 68 or 69, wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2 θ): 7.3 $\pm$ 0.2, 10.8 $\pm$ 0.2, 13.8 $\pm$ 0.2, 16.6 $\pm$ 0.2, 17.8 $\pm$ 0.2, 18.4 $\pm$ 0.2, 19.5 $\pm$ 0.2, 20.3 $\pm$ 0.2, 21.2 $\pm$ 0.2, and 24.3 $\pm$ 0.2.

10 71. The crystalline compound of any one of claims 68-70, wherein the crystalline compound exhibits an X-ray powder diffraction pattern substantially the same as depicted in FIG. 7A.

72. The crystalline compound of any one of claims 68-71, wherein the crystalline
15 compound has a melting point onset as determined by differential scanning calorimetry at about 103 °C.

73. The crystalline compound of any one of claims 68-72, wherein the crystalline
20 compound has a differential scanning calorimetry curve substantially the same as shown in FIG. 7B.

74. A crystalline compound of formula:



wherein the crystalline compound exhibits an X-ray powder diffraction pattern
25 comprising peaks at the following diffraction angles (2 θ): 6.9 $\pm$ 0.2, 16.4 $\pm$ 0.2, and 19.5 $\pm$ 0.2.

75. The crystalline compound of claim 74, wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2 θ): 6.9 $\pm$ 0.2, 16.4 $\pm$ 0.2, 17.4 $\pm$ 0.2, 18.0 $\pm$ 0.2, 19.5 $\pm$ 0.2, and 20.8 $\pm$ 0.2.

30

76. The crystalline compound of claim 74 or 75, wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 6.9 ± 0.2 , 11.2 ± 0.2 , 13.6 ± 0.2 , 13.9 ± 0.2 , 16.4 ± 0.2 , 17.4 ± 0.2 , 18.0 ± 0.2 , 19.5 ± 0.2 , and 20.8 ± 0.2 .


5

77. The crystalline compound of any one of claims 74-76, wherein the crystalline compound exhibits an X-ray powder diffraction pattern substantially the same as depicted in FIG. 8A.

10 78. The crystalline compound of any one of claims 74-77, wherein the crystalline compound has a melting point onset as determined by differential scanning calorimetry at about $133\text{ }^{\circ}\text{C}$.

15 79. The crystalline compound of any one of claims 74-78, wherein the crystalline compound has a differential scanning calorimetry curve substantially the same as shown in FIG. 8B.

80. A crystalline compound of formula:



20 wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 9.9 ± 0.2 , 19.8 ± 0.2 , and 23.7 ± 0.2 .

81. The crystalline compound of claim 80, wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):

25 9.9 ± 0.2 , 12.3 ± 0.2 , 14.1 ± 0.2 , 19.8 ± 0.2 , 20.7 ± 0.2 , and 23.7 ± 0.2 .

82. The crystalline compound of claim 80 or 81, wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 7.3 ± 0.2 , 9.9 ± 0.2 , 12.3 ± 0.2 , 14.1 ± 0.2 , 16.5 ± 0.2 , 17.2 ± 0.2 , 19.8 ± 0.2 , 20.7 ± 0.2 ,
30 23.7 ± 0.2 , 24.8 ± 0.2 , 27.7 ± 0.2 , and 29.1 ± 0.2 .


83. The crystalline compound of any one of claims 80-82, wherein the crystalline compound exhibits an X-ray powder diffraction pattern substantially the same as depicted in FIG. 9A.

5

84. The crystalline compound of any one of claims 80-83, wherein the crystalline compound has a melting point onset as determined by differential scanning calorimetry at about 111 °C.

10 85. The crystalline compound of any one of claims 80-84, wherein the crystalline compound has a differential scanning calorimetry curve substantially the same as shown in FIG. 9B.

86. A crystalline compound of formula:



15

wherein the crystalline compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2 θ): 9.3 $\pm$ 0.2, 18.8 $\pm$ 0.2, and 21.4 $\pm$ 0.2.

87. The crystalline compound of claim 86, wherein the crystalline compound exhibits an
20 X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2 θ): 9.3 $\pm$ 0.2, 16.1 $\pm$ 0.2, 18.8 $\pm$ 0.2, 21.1 $\pm$ 0.2, 21.4 $\pm$ 0.2, and 21.6 $\pm$ 0.2.

88. The crystalline compound of claim 86 or 87, wherein the crystalline compound
exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction
25 angles (2 θ): 9.3 $\pm$ 0.2, 16.1 $\pm$ 0.2, 18.8 $\pm$ 0.2, 21.1 $\pm$ 0.2, 21.4 $\pm$ 0.2, 21.6 $\pm$ 0.2, 22.6 $\pm$ 0.2, 23.9 $\pm$ 0.2, 26.0 $\pm$ 0.2, and 26.4 $\pm$ 0.2.

89. The crystalline compound of any one of claims 86-88, wherein the crystalline
compound exhibits an X-ray powder diffraction pattern substantially the same as depicted in
30 FIG. 1A.

90. The crystalline compound of any one of claims 86-89, wherein the crystalline compound has a melting point onset as determined by differential scanning calorimetry at about 122 °C.
- 5
91. The crystalline compound of any one of claims 86-90, wherein the crystalline compound has a differential scanning calorimetry curve substantially the same as shown in FIG. 1B.
- 10
92. The crystalline compound of any one of claims 38-91, wherein the X-ray powder diffraction pattern was obtained using Cu K α radiation.
93. A pharmaceutical composition comprising a compound of any one of claims 1-92, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
- 15
94. A composition comprising a compound of any one of claims 1-92, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
95. A pharmaceutical composition comprising a compound of any one of claims 1-92, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier as claimed in claim 93, for use in medicine.
- 20
96. A method of treating a condition relating to aberrant function of a sodium ion channel in a subject, comprising administering to the subject a therapeutically effective amount of a compound of any one of claims 1-92, or a pharmaceutically acceptable salt thereof, a composition of claim 94, or a pharmaceutical composition of claim 93 or 95.
- 25
97. The method of claim 96, wherein the condition is a neurological or psychiatric disorder.
- 30
98. The method of claim 96 or 97, wherein the condition is epilepsy or an epilepsy syndrome.
99. The method of any one of claims 96-98, wherein the condition is a genetic epilepsy or a genetic epilepsy syndrome.

100. The method of any one of claims 96-99, wherein the condition is a pediatric epilepsy or a pediatric epilepsy syndrome.

5 101. The method of any one of claims 96-100, wherein the condition is epileptic encephalopathy.

102. The method of claim 101, wherein the epileptic encephalopathy is selected from the group consisting of Dravet syndrome, infantile spasms, or Lennox-Gastaut syndrome.

10

103. The method of claim 101 or 102, wherein the condition is selected from the group consisting of epileptic encephalopathy, epileptic encephalopathy with SCN1A, SCN2A, SCN8A mutations, early infantile epileptic encephalopathy, Dravet syndrome, Dravet syndrome with SCN1A mutation, generalized epilepsy with febrile seizures, intractable childhood epilepsy with generalized tonic-clonic seizures, infantile spasms, benign familial neonatal-infantile seizures, SCN2A epileptic encephalopathy, focal epilepsy with SCN3A mutation, cryptogenic pediatric partial epilepsy with SCN3A mutation, SCN8A epileptic encephalopathy, sudden unexpected death in epilepsy, Rasmussen encephalitis, malignant migrating partial seizures of infancy, autosomal dominant nocturnal frontal lobe epilepsy, sudden expected death in epilepsy (SUDEP), KCNQ2 epileptic encephalopathy, and KCNT1 epileptic encephalopathy.

15
20

104. A method of treating a neurological disorder or a psychiatric disorder, wherein the method comprises administering to a subject in need thereof the compound of any one of claims 1-92, or a pharmaceutically acceptable salt thereof, a composition of claim 94, or a pharmaceutical composition of claim 93 or 95.

25

105. A method of treating a pain, wherein the method comprises administering to a subject in need thereof a compound of any one of claims 1-92, or a pharmaceutically acceptable salt thereof, a composition of claim 94, or a pharmaceutical composition of claim 93 or 95.

30

106. A composition comprising a compound of any one of claims 1-92, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 93 or 95, or the composition of claim 94 for treating a condition relating to aberrant function of a sodium ion channel in a subject.

107. The composition or the pharmaceutical composition of claim 106, wherein the condition is a neurological or psychiatric disorder.
- 5 108. The composition or the pharmaceutical composition of claim 106, wherein the condition is a pain.
109. The composition or the pharmaceutical composition of claim 106 or 107, wherein the condition is epilepsy or an epilepsy syndrome.
- 10 110. The composition or the pharmaceutical composition of any one of claims 106, 107, or 109, wherein the condition is a genetic epilepsy or a genetic epilepsy syndrome.
111. The composition or the pharmaceutical composition of any one of claims 106, 107,
15 109, or 110, wherein the condition is a pediatric epilepsy or a pediatric epilepsy syndrome.
112. The composition or the pharmaceutical composition of any one of claims 106, 107, and 109-111, wherein the condition is epileptic encephalopathy.
- 20 113. The composition or the pharmaceutical composition of claim 112, wherein the epileptic encephalopathy is selected from the group consisting of Dravet syndrome, infantile spasms, and Lennox-Gastaut syndrome.
114. The composition or the pharmaceutical composition of claim 112 or 113, wherein the
25 condition is selected from the group consisting of epileptic encephalopathy, epileptic encephalopathy with SCN1A, SCN2A, SCN8A mutations, early infantile epileptic encephalopathy, Dravet syndrome, Dravet syndrome with SCN1A mutation, generalized epilepsy with febrile seizures, intractable childhood epilepsy with generalized tonic-clonic seizures, infantile spasms, benign familial neonatal-infantile seizures, SCN2A epileptic
30 encephalopathy, focal epilepsy with SCN3A mutation, cryptogenic pediatric partial epilepsy with SCN3A mutation, SCN8A epileptic encephalopathy, sudden unexpected death in epilepsy, Rasmussen encephalitis, malignant migrating partial seizures of infancy, autosomal dominant nocturnal frontal lobe epilepsy, sudden expected death in epilepsy (SUDEP), KCNQ2 epileptic encephalopathy, and KCNT1 epileptic encephalopathy.

115. A composition comprising a compound of any one of claims 1-92 or a pharmaceutically acceptable salt thereof, the pharmaceutical composition of claim 93 or 95, or the composition of claim 94 for treating a neurological disorder or a psychiatric disorder.

5